

INTREPID Alliance Antiviral Landscape: Overview of 13 Priority Viral Families*

As of July 12, 2024, for the 13 viral families with greatest risk of pandemic potential, clinical phase & approved antiviral compounds fall into 9 of 13 and preclinical into 10 of 13.

Primarily Respiratory Transmission:

Viral Family	Disease Indication (n)**	
	Preclinical	Clinical
Adenoviridae	HuAdeno A-G (3)	HuAdeno A-G (0)
Coronaviridae	COVID-19 (73) MERS-CoV (5) SARS-CoV-1 (5)	COVID-19 (29)
Orthomyxoviridae	Influenza (12)	Influenza (9)
Paramyxoviridae	Hendra virus (3) Measles (1) Nipah virus (3) Parainfluenza (0)	X
Picornaviridae	X	Polio (2) Rhinovirus (1)

X = absence of preclinical or clinical phase antivirals


Primarily Contact/Vector-Mediated Transmission:

Viral Family	Disease Indication (n)**	
	Preclinical	Clinical
Arenaviridae	Lassa fever (1) Argentine hem. fever (0) Luján hem. fever (0)	Lassa fever (1) Chapare hem. fever (1)
Filoviridae	Ebola (1) Marburg (3)	Ebola (2)
Flaviviridae	Dengue (4) West Nile (1) Yellow fever (3) Zika (2)	Dengue (3) Japanese encephalitis (0)
Hantaviridae	Hantavirus (1)	X
Nairoviridae	X	Crimean Congo hem. fever (2)
Peribunyaviridae	X	X
Poxviridae	Mpox (2) Smallpox/Other poxviruses (1)	Mpox (1)
Togaviridae	Chikungunya (3)	X

*As of July 12, 2024; **Number of compounds in ongoing development; those with (0) only have “Archived” compounds.

The Majority of Clinical Phase Antiviral Compound/Indications Are Targeting Coronaviruses and Orthomyxoviruses*


% Clinical Phase Antiviral Compound/Indications by Virus Family (July 2024, N=79)



*As of July 12, 2024. Adenoviridae has 1 clinical phase program listed in Archived.

The Majority of Clinical Phase Antiviral Compound/Indications Are Targeting Coronaviruses and Orthomyxoviruses*


% Clinical Phase Antiviral Compound/Indications by Virus Family (July 2024, N=79)



*As of July 12, 2024

"Promising" Clinical Compounds Analysis (July 2024)*


Unapproved Compounds (Promising and Watch & Wait) by Virus Family (N=44)



*As of July 12, 2024

“Promising” Compounds Analysis (July 2024)*

Novel Compound/Indications (Promising and Watch & Wait) by Phase of Development (N=44)



*As of July 12, 2024



INTREPID ALLIANCE

INTERNATIONAL READINESS FOR PREVENTING INFECTIOUS VIRAL DISEASE

**Interested
in engaging
with us?**

We welcome all feedback through [our online portal](#). As with previous listings, developers are invited to submit non-confidential information on their compound candidates. All reports are updated quarterly.

For more information, contact nina@intrepidalliance.org.

 intrepidalliance.org

 linkedin.com/company/intrepid-alliance